DK1032671T3 - Mammalt cytokin-lignende polypeptid-10 - Google Patents

Mammalt cytokin-lignende polypeptid-10

Info

Publication number
DK1032671T3
DK1032671T3 DK98960493T DK98960493T DK1032671T3 DK 1032671 T3 DK1032671 T3 DK 1032671T3 DK 98960493 T DK98960493 T DK 98960493T DK 98960493 T DK98960493 T DK 98960493T DK 1032671 T3 DK1032671 T3 DK 1032671T3
Authority
DK
Denmark
Prior art keywords
polypeptide
prevention
antibody
treatment
mammalian cytokine
Prior art date
Application number
DK98960493T
Other languages
Danish (da)
English (en)
Inventor
Angelika Grossmann
Darrell C Conklin
Betty A Haldeman
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1032671T3 publication Critical patent/DK1032671T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
DK98960493T 1997-11-26 1998-11-25 Mammalt cytokin-lignende polypeptid-10 DK1032671T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26

Publications (1)

Publication Number Publication Date
DK1032671T3 true DK1032671T3 (da) 2004-10-11

Family

ID=25526742

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98960493T DK1032671T3 (da) 1997-11-26 1998-11-25 Mammalt cytokin-lignende polypeptid-10

Country Status (20)

Country Link
EP (3) EP1032671B1 (de)
JP (2) JP5191619B2 (de)
KR (1) KR100574387B1 (de)
CN (2) CN1618969A (de)
AT (1) ATE269902T1 (de)
AU (1) AU739420B2 (de)
BR (1) BR9814904A (de)
CA (1) CA2312000C (de)
CZ (1) CZ300849B6 (de)
DE (1) DE69824755T2 (de)
DK (1) DK1032671T3 (de)
EA (2) EA005581B1 (de)
ES (1) ES2218872T3 (de)
HU (1) HU227703B1 (de)
IL (2) IL136076A0 (de)
NO (2) NO326561B1 (de)
NZ (1) NZ504751A (de)
PL (2) PL195304B1 (de)
UA (2) UA73275C2 (de)
WO (1) WO1999027103A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
ES2387394T3 (es) * 1999-12-23 2012-09-21 Zymogenetics, Inc. Procedimiento de tratamiento de la inflamación
RU2279441C2 (ru) 1999-12-23 2006-07-10 Займодженетикс, Инк. Выделенный растворимый il-20 рецептор (варианты)
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
AU2001290524A1 (en) 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
ATE333888T1 (de) 2000-09-15 2006-08-15 Zymogenetics Inc Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
US20030032167A1 (en) * 2000-10-20 2003-02-13 Conklin Darrell C. Secreted alpha-helical protein zlmda24
WO2002058724A2 (en) * 2001-01-26 2002-08-01 Eli Lilly And Company Use of lp82 to treat body weight disorders
US7101539B2 (en) 2001-02-28 2006-09-05 Eli Lilly And Company Use of LP82 to treat hematopoietic disorders
US20040204351A1 (en) * 2001-10-22 2004-10-14 Rowlinson Scott William Soluble proteins that inhibit cytokine signal transduction pathways
WO2003051384A1 (en) 2001-12-17 2003-06-26 Zymogenetics, Inc. Method for treating cervical cancer
DE602004028347D1 (de) * 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
EP1653995A1 (de) 2003-08-08 2006-05-10 Novo Nordisk A/S Interleukin-20 zur behandlung und diagnose von mit neovaskularization verbunden zuständen
EP1697418A2 (de) 2003-11-21 2006-09-06 ZymoGenetics, Inc. Anti-il-20-rezeptor-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
ATE506433T1 (de) 2003-12-19 2011-05-15 Novo Nordisk As Prozessierung von peptiden und proteinen
EP2033662B1 (de) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase vermittelte konjugation von peptiden.
CA2558811A1 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
EA015706B1 (ru) 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
JP5588970B2 (ja) 2008-05-27 2014-09-10 ダコ・デンマーク・エー／エス ハイブリダイゼーション組成物及び方法
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
JP5860699B2 (ja) * 2008-10-07 2016-02-16 ナショナル チェン クン ユニバーシティ 骨粗鬆症の治療のためのｉｌ−２０アンタゴニストの使用
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (de) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren
CA2864523C (en) * 2012-03-05 2019-02-05 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
WO2018200620A1 (en) 2017-04-25 2018-11-01 National Cheng Kung University Use of il-20 antagonists for treating eye diseases
BR112022006862A2 (pt) * 2019-10-10 2022-07-05 Univ New York State Res Found Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637856D1 (en) * 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
ES2387394T3 (es) * 1999-12-23 2012-09-21 Zymogenetics, Inc. Procedimiento de tratamiento de la inflamación

Also Published As

Publication number Publication date
IL136076A (en) 2007-12-03
UA73275C2 (en) 2005-07-15
EP1719780A3 (de) 2006-12-20
NO20002698D0 (no) 2000-05-26
CZ300849B6 (cs) 2009-08-26
PL195304B1 (pl) 2007-08-31
EP1719780A2 (de) 2006-11-08
ATE269902T1 (de) 2004-07-15
HUP0100436A2 (hu) 2001-06-28
PL198687B1 (pl) 2008-07-31
KR100574387B1 (ko) 2006-04-27
DE69824755T2 (de) 2005-08-04
KR20010032490A (ko) 2001-04-25
EA010741B1 (ru) 2008-10-30
EP1032671A1 (de) 2000-09-06
JP2010187698A (ja) 2010-09-02
IL136076A0 (en) 2001-05-20
ES2218872T3 (es) 2004-11-16
NO329731B1 (no) 2010-12-13
WO1999027103A1 (en) 1999-06-03
BR9814904A (pt) 2000-10-03
JP5191619B2 (ja) 2013-05-08
JP5331054B2 (ja) 2013-10-30
CA2312000C (en) 2013-03-26
AU739420B2 (en) 2001-10-11
CA2312000A1 (en) 1999-06-03
HU227703B1 (en) 2011-12-28
NO20002698L (no) 2000-07-20
NO20074516L (no) 2000-07-20
EA200401501A1 (ru) 2006-02-24
NZ504751A (en) 2001-10-26
EP1032671B1 (de) 2004-06-23
EP1424393A3 (de) 2004-06-09
EP1424393A2 (de) 2004-06-02
UA86350C2 (en) 2009-04-27
CN1618969A (zh) 2005-05-25
CZ20001910A3 (cs) 2000-11-15
JP2001524313A (ja) 2001-12-04
CN1247780C (zh) 2006-03-29
AU1607799A (en) 1999-06-15
EA200000565A1 (ru) 2000-12-25
DE69824755D1 (de) 2004-07-29
EA005581B1 (ru) 2005-04-28
HUP0100436A3 (en) 2003-08-28
PL340755A1 (en) 2001-02-26
CN1282372A (zh) 2001-01-31
NO326561B1 (no) 2009-01-12

Similar Documents

Publication Publication Date Title
NO20002698L (no) Cytokinlignende pattedyrpolypeptid 10
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
RU2000124084A (ru) Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты)
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
EP1466925A4 (de) Antikörper gegen den fibroblastenwachstumsfaktor 23
SE8901687D0 (sv) Fibronectin binding protein as well as its preparation
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
EP1501936A4 (de) Cytokin-proteinfamilie
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
ATE140008T1 (de) Polypeptid
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
ATE240398T1 (de) Von kaposi-sarkom assoziiertem herpes-virus (kshv,hhv-8) kodiertes polypeptid und dessen verwendung in diagnostik und therapie
ATE366810T1 (de) Menschliche p51-gene und deren genprodukte
DE69306273D1 (de) Mitogen für die glatte Muskulatur und dessen kodierende DNS
KR950704352A (ko) 테라포시데 아포노펠마로부터의 칼슘 통로 차단 폴리펩티드(calcium channel blocking polypeptides from theraphosidae aphonopelma)
DE60325227D1 (de)
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
KR930019827A (ko) 신규 폴리펩티드 및 이를 암호하는 dna
MX9504057A (es) Proteina que tiene actividad tpo.
NZ606260A (en) Novel polypeptides involved in immune response
WO1999060117A3 (fr) Polypeptide prax-1